Business Context and Reporting Period
Olema Pharmaceuticals, Inc. filed this Form 8-K on May 15, 2024, under Items 7.01 and 8.01 to report interim results from an ongoing Phase 1b/2 study of palazestrant (OP-1250) in combination with ribociclib for ER+/HER2- advanced or metastatic breast cancer. The data cutoff was March 13, 2024, and the results were scheduled for presentation at the 2024 ESMO Breast Cancer Annual Congress.
Key Financial and Operating Metrics
- This filing does not provide revenue, net income, cash flow, margins, debt, liquidity, or other financial statement metrics.
- As of the data cutoff, 50 patients had been treated; the study was fully enrolled at 60 patients.
- Forty-four patients received the palazestrant recommended Phase 2 dose of 120 mg once daily with ribociclib 600 mg once daily.
- Sixty-six percent of patients, or 33 of 50, remained on treatment at the data cutoff; the longest treatment duration was 44 weeks.
- Clinical benefit rate was 85% overall among eligible patients, 83% in ESR1-mutant patients, 86% in ESR1-wild-type patients, and 83% in patients previously treated with a CDK4/6 inhibitor.
- Five partial responses were observed among 23 response-evaluable patients, including two confirmed and three unconfirmed responses.
Material Changes and Clinical Findings
- The combination was reported as well tolerated through 120 mg of palazestrant with no new safety signals, no dose-limiting toxicities, and no maximum tolerated dose reached.
- Ten patients required ribociclib dose reductions for QTcF prolongation, neutropenia, or fatigue. Two patients discontinued ribociclib for neutropenia but continued palazestrant.
- No patients discontinued palazestrant because of a treatment-related adverse event; neutropenia was reversible in all affected patients.
- Palazestrant did not materially affect ribociclib exposure, and ribociclib did not have a clinically meaningful effect on palazestrant exposure.
- The reported findings support continued development of palazestrant with ribociclib, including potential first-line treatment of ER+/HER2- advanced or metastatic breast cancer.
Guidance, Outlook, Risks, and Unusual Items
Management did not provide financial guidance in this filing. The company characterized the efficacy data as preliminary and from a maturing dataset. The filing contains forward-looking statements regarding palazestrant’s safety, efficacy, development plans, combination potential, and prospects as an endocrine therapy. These statements are subject to clinical-development, regulatory, safety, efficacy, enrollment, timing, financing, and other risks described in Olema’s Form 10-Q for the quarter ended March 31, 2024, and subsequent SEC filings.
Exhibits 99.1 and 99.2 were furnished, rather than filed, and are not incorporated by reference except where expressly stated.
Facts Investors Should Verify
- Whether subsequent data confirm the preliminary response and clinical benefit rates.
- The durability of responses and disease stabilization as follow-up matures.
- Whether the reported safety profile remains consistent in the fully enrolled 60-patient study.
- The design, timing, and regulatory status of planned or ongoing palazestrant studies, particularly in the first-line setting.
- Olema’s cash runway, financing requirements, operating losses, and liquidity from its latest Form 10-Q, which are not included in this 8-K.